𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonist

✍ Scribed by J. Maj; Z. Rogóż; G. Skuza; H. Sowińska

Publisher
Springer
Year
1989
Tongue
English
Weight
516 KB
Volume
78
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antidepressant drugs given repeatedly in
Antidepressant drugs given repeatedly increase the behavioural effects of methoxamine
✍ J. Maj; Z. Rogóz̊; G. Skuza 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB

In this study we investigated the effect of imipramine, citalopram and mianserin on behavioural effects of methoxamine, an a,-adrenoceptor agonist, in the rat. Methoxamine (25 and 50 pg) given into the brain lateral ventricle, increases the exploratory activity assessed in the open field test (time

Effect of the putative dopamine D1 agoni
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease
✍ L. Verhagen Metman; P. J. Blanchet; D. de Jong; M. M. Mouradian; Dr. T. N. Chase 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 433 KB

## Abstract The ergoline derivative FCE 23884 acts as a dopamine D~1~ agonist in untreated parkinsonian animals and as a D~2~ antagonist in animals whose dopamine system is intact or levodopa treated. To evaluate whether this dual action might benefit patients with Parkinson's disease (PD) who have

Biphasic effects of dopamine D-2 recepto
Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat
✍ Jaime M. Monti; Marjorie Hawkins; Héctor Jantos; Luisa D'Angelo; Mónica Fernánde 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 670 KB

The effects of the dopamine (DA) receptor agonists apomorphine, bromocriptine and pergolide were compared with those produced by a DA receptor antagonist, haloperidol, in rats implanted with electrodes for chronic sleep recordings. Apomorphine (0.025-2.0 mg/kg) and bromocriptine (0.25-6.0 mg/kg) ind

Antiparkinsonian effects of the novel D3
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors
✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept

Protective effect of dopamine D2 agonist
Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade
✍ Takeshi Kihara; Shun Shimohama; Hideyuki Sawada; Kazuhiro Honda; Tomoki Nakamizo 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract Glutamate, one of the excitatory neurotransmitters, contributes to the neuronal death associated with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and with ischemia. In Alzheimer's disease brains, there is a decreased number of dopamine D2 receptors,